• Home
  •  / Protalix BioTherapeutics

Protalix BioTherapeutics

OverviewSuggest Edit

Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by our proprietary ProCellEx plant cell-based protein expression system. The Company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of Gaucher's Disease. The Company has concluded phase III studies for this drug and is currently undergoing FDA review. Treatment is currently being provided by Protalix to Gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide.

TypePublic
Founded1994
HQKarmiel, ILMap
Websiteprotalix.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)184(-3%)
Revenue (FY, 2019)$54.7 M(+185%)
Share Price (Jan 2021)₪1.5 K(+3%)
Cybersecurity ratingFMore

Key People/Management at Protalix BioTherapeutics

Dror Bashan

Dror Bashan

President & Chief Executive Officer, Director
Zeev Bronfeld

Zeev Bronfeld

Chairman
Einat Brill-Almon

Einat Brill-Almon

Senior Vice President, Product Development
David Granot

David Granot

Director
Pol F. Boudes

Pol F. Boudes

Director
Yaron Naos

Yaron Naos

Senior Vice President, Operations
Show more

Protalix BioTherapeutics Office Locations

Protalix BioTherapeutics has an office in Karmiel
Karmiel, IL (HQ)
Snunit St 2
Show all (1)

Protalix BioTherapeutics Financials and Metrics

Protalix BioTherapeutics Revenue

Protalix BioTherapeutics's revenue was reported to be $54.69 m in FY, 2019
USD

Revenue (Q3, 2020)

10.8m

Gross profit (Q3, 2020)

7.9m

Gross profit margin (Q3, 2020), %

73.4%

Net income (Q3, 2020)

(4.4m)

EBIT (Q3, 2020)

(2.6m)

Market capitalization (20-Jan-2021)

492.1m

Closing stock price (20-Jan-2021)

1.5k

Cash (30-Sept-2020)

13.5m

EV

542.1m
Protalix BioTherapeutics's current market capitalization is ₪492.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

8.4m34.9m10.5m13.7m4.4m9.2m19.2m54.7m

Cost of goods sold

1.5m8.1m5.4m9.1m730.0k8.4m15.2m9.3m10.9m

Gross profit

6.9m26.7m5.1m4.6m3.6m801.0k4.0m43.8m

Gross profit Margin, %

82%77%48%34%83%9%21%80%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

764.0k1.1m3.9m26.1m3.7m3.6m2.3m2.3m2.4m2.4m4.4m3.8m679.0k1.8m4.7m2.9m6.4m7.5m4.6m2.0m663.0k21.6m11.0m10.8m

Cost of goods sold

132.0k220.0k1.3m3.3m2.4m971.0k1.3m1.6m1.6m1.8m2.4m2.0m2.3m523.0k1.7m4.2m2.1m5.5m6.1m2.9m2.2m1.9m2.0m2.7m3.2m3.4m1.8m2.9m

Gross profit

632.0k912.0k2.5m22.8m1.4m2.6m946.0k697.0k820.0k598.0k2.0m1.7m156.0k94.0k422.0k801.0k835.0k1.5m1.6m(177.0k)(1.3m)18.2m9.1m7.9m

Gross profit Margin, %

83%81%66%87%36%73%42%31%34%25%45%46%23%5%9%28%13%19%36%(9%)(189%)84%83%73%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

27.0m52.0m86.4m54.8m76.4m63.3m51.2m37.8m17.8m

Accounts Receivable

1.4m1.4m2.1m1.9m693.0k1.7m4.7m4.7m

Prepaid Expenses

251.0k2.2m1.7m2.3m1.9m1.9m

Inventories

279.0k4.0m8.0m6.7m5.8m5.2m7.8m8.6m8.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

44.1m34.6m45.6m59.3m50.2m41.9m33.1m91.4m71.1m60.3m48.0m43.2m34.2m66.7m54.6m51.3m48.0m34.5m33.5m41.3m28.3m41.9m30.4m25.1m21.4m14.2m4.8m13.5m

Accounts Receivable

1.7m2.3m815.0k1.5m4.0m1.7m2.0m2.1m2.1m2.0m1.8m1.9m4.6m1.5m2.1m2.7m3.0m7.3m4.8m5.2m4.9m8.6m7.3m8.7m8.9m5.3m3.1m

Prepaid Expenses

2.9m2.3m2.7m2.9m5.1m1.0m3.5m4.1m2.7m2.6m2.5m2.6m1.7m2.2m2.8m

Inventories

537.0k427.0k263.0k1.0m2.1m5.8m7.2m7.6m7.1m6.8m6.9m6.4m6.3m5.7m6.1m4.9m7.1m7.1m7.5m7.0m7.0m8.0m6.7m7.0m7.5m9.5m11.1m13.3m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(36.5m)(11.6m)(27.8m)(29.9m)58.0m(29.4m)(85.3m)(26.5m)(18.3m)

Depreciation and Amortization

3.1m2.4m2.0m1.9m1.7m1.6m

Inventories

910.0k(3.8m)(3.9m)1.3m(2.3m)522.0k(2.6m)(736.0k)414.0k

Accounts Payable

6.1m3.0m(1.3m)954.0k(1.9m)2.1m4.9m(761.0k)2.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(18.7m)(27.6m)(5.9m)3.7m(1.7m)(4.3m)(11.2m)(16.9m)(13.5m)(21.5m)(6.0m)(11.0m)(14.9m)(8.6m)(19.5m)(26.7m)(59.1m)(58.7m)(70.1m)(9.4m)(20.7m)(36.2m)(7.3m)(15.0m)(18.6m)1.7m(2.5m)(6.9m)

Depreciation and Amortization

616.0k1.2m1.8m516.0k1.0m1.5m492.0k986.0k1.5m430.0k846.0k1.3m405.0k784.0k1.2m376.0k710.0k1.0m

Inventories

652.0k762.0k16.0k(750.0k)(1.8m)(1.7m)(3.2m)(3.5m)822.0k1.1m(212.0k)299.0k328.0k30.0k(300.0k)907.0k(1.9m)(1.8m)(2.2m)814.0k855.0k(126.0k)1.9m1.6m1.0m(1.3m)(2.9m)(5.1m)

Accounts Payable

4.8m4.4m(242.0k)2.1m369.0k(3.0m)(3.0m)(5.4m)180.0k(1.7m)(893.0k)(1.9m)(4.4m)(470.0k)1.3m367.0k2.4m5.4m8.7m(1.0m)(1.3m)(1.8m)864.0k1.5m4.9m2.6m309.0k3.3m
show all
USDQ2, 2011

Debt/Equity

-0.5 x

Debt/Assets

0.1 x

Financial Leverage

-8.3 x
Show all financial metrics

Protalix BioTherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

F

58/100

Learn more about our premium products
SecurityScorecard logo

Protalix BioTherapeutics Online and Social Media Presence

Protalix BioTherapeutics's Trends

Embed Graph

Protalix BioTherapeutics News and Updates

January 04, 2021

Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January

CARMIEL, Israel, Jan. 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...
December 30, 2020

Protalix BioTherapeutics Issues 2020 Letter to Shareholders

CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...
December 03, 2020

Pharmaceutical Plant Protein Market New Business Experts Ideas By Duynie Group, Axiom Foods, Greenovation Biotech, iBio, Plant Protalix Biotherapeutics, Ventria BioscienceForm,

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 08, 2020

Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards

CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...
September 08, 2020

Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...
June 01, 2020

Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update

CARMIEL, Israel, June 1, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...
Show more

Protalix BioTherapeutics Blogs

November 05, 2020

Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference

Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference Content Import Thu, 11/05/2020 - 06:50 Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference Nov 5 This release is a backfill from a Ne…
October 29, 2020

Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

CARMIEL, Israel , Oct. 29, 2020 /PRNewswire/ --  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based
October 29, 2020

Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Announced FDA acceptance of BLA filing of PRX-102 for the treatment of Fabry disease   Top-line data from the BRIGHT study expected by end of first quarter, 2021   Management to host conference call and live webcast today, October 29, at 8:30 am ET CARMIEL, Israel , Oct.
October 26, 2020

Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable

Management and KOL scheduled to present on Wednesday, October 28 at 10:00 a.m. EDT CARMIEL, Israel , Oct. 26, 2020 /PRNewswire/ --  Protalix BioTherapeutics, Inc.  (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of
October 22, 2020

Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Oct. 22, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins

 Protalix BioTherapeutics Frequently Asked Questions

  • When was Protalix BioTherapeutics founded?

    Protalix BioTherapeutics was founded in 1994.

  • Who are Protalix BioTherapeutics key executives?

    Protalix BioTherapeutics's key executives are Dror Bashan, Zeev Bronfeld and Einat Brill-Almon.

  • How many employees does Protalix BioTherapeutics have?

    Protalix BioTherapeutics has 184 employees.

  • What is Protalix BioTherapeutics revenue?

    Latest Protalix BioTherapeutics annual revenue is $54.7 m.

  • What is Protalix BioTherapeutics revenue per employee?

    Latest Protalix BioTherapeutics revenue per employee is $297.2 k.

  • Who are Protalix BioTherapeutics competitors?

    Competitors of Protalix BioTherapeutics include Pharming Group, GT Biopharma and Regulus Therapeutics.

  • Where is Protalix BioTherapeutics headquarters?

    Protalix BioTherapeutics headquarters is located at Snunit St 2, Karmiel.

  • Where are Protalix BioTherapeutics offices?

    Protalix BioTherapeutics has an office in Karmiel.

  • How many offices does Protalix BioTherapeutics have?

    Protalix BioTherapeutics has 1 office.